Changes in joint health were evaluated1

In a post hoc study of patients ≥ 12 years of age treated with ELOCTATE prophylaxis

Study Design

Study Design1

  • This post hoc study assessed change in joint health among 47 adult and adolescent males (≥12 years of age) with severe hemophilia A who were treated with ELOCTATE prophylaxis
  • Subjects completed the A-LONG pivotal trial, enrolled in the ASPIRE extension study (data cutoff of December 8, 2014), and had available mHJHS data
  • Forty-seven subjects had mHJHS data at all 4 time points (A-LONG baseline, ASPIRE baseline, Year 1, and Year 2)
  • Joint health assessments included the change in mHJHS from A-LONG baseline to follow-up visits and comparisons of individual mHJHS domains. In addition, factors such as target joints, weight-bearing and non–weight-bearing joints, and prestudy dosing regimen were assessed for impact on mHJHS. Negative values indicate improvement

Study Limitations1

  • Data are reported from a post hoc analysis that was not powered to show statistical significance. There was a small sample size, no control group, and potential for interobserver variability
  • The mHJHS is not a validated tool
  • Further studies are needed to confirm these findings as well as the effect of improvements in joint health on overall quality of life
Improvement in Total mHJHS Was Observed Over Time

Improvement in Total mHJHS Was Observed Over Time

Improvement in total mHJHS was observed over time

From A‐LONG Baseline
                                to ASPIRE Year 2, patients treated with
                                factor prior to switching to ELOCTATE
                                experienced improvements in total
                                mHJHS score.

mHJHS=modified Hemophilia Joint Health Score; SHL=standard half-life.

Published in
                                        Haemophilia

See the research:

Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein

Oldenburg J, Kulkarni R, Srivastava A, et al. Haemophilia. 2018;24(1):77-84.

TAKE ME TO THE ARTICLE

See the research:

Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein

Oldenburg J, Kulkarni R, Srivastava A, et al. Haemophilia. 2018;24(1):77-84.

TAKE ME TO THE ARTICLE

Swelling, range of motion, and strength components
contributed most to changes in joint health scores1

Calculate the
recommended ELOCTATE
dose for your patients
Sanofi Logo

This site is intended for United States Residents only.

© 2022 Genzyme Corporation. All rights reserved.

ELOCTATE and Sanofi are registered trademarks of Sanofi or an affiliate. MyELOCTATE is owned by Genzyme Corporation.
All the other trademarks above are the property of their respective owners, who have no affiliation or relationship with Sanofi.

MAT-US-2003075-v5.0-03/2022 Last Updated: March 2022